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BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair
cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy
in patients with metastatic oesophageal squamous cell cancer.
METHOD: A total of 113 patients with metastatic oesophageal squamous cell cancer were treated with XP chemotherapy at the
Samsung Medical Center between 2003 and 2007, of whom 72 had available clinical data and paraffin blocks for
immunohistochemistry of TS, TP, and ERCC1.
RESULTS: The median age of the 72 patients was 62 years. The overall response rate (RR) was 51.4%. The median progression-free
survival (PFS) and overall survival (OS) were 4.2 and 12.0 months, respectively. High expression of TS and TP was associated with a
higher RR than was low expression of TS and TP (54.1 vs 40.5%, P¼0.022). Strong ERCC1 expression and a low TS score were
identified as unfavourable independent risk factors for PFS (HR 10.71, 95% confidence interval (CI) 2.1–54.7, P¼0.004 for strong
ERCC1 expression; and HR 2.9, 95% CI 1.0–7.9, P¼0.044 for low TS score). Strong ERCC1 expression was identified as an
unfavourable independent risk factor for OS (HR 3.73, 95% CI 1.39–10.0, P¼0.009).
CONCLUSION: These data indicate that expression of TS, TP, and ERCC1 may be predictive markers for response and survival in
patients with metastatic oesophageal squamous cell cancer receiving XP chemotherapy.
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Oesophageal cancer is the eight most frequent malignancy and the
fourth highest cause of cancer-related mortality, with almost
500000 new patients diagnosed annually worldwide (Kamangar
et al, 2006; Tebbutt et al, 2010). The most frequent histological
type of oesophageal cancer is squamous cell carcinoma (SCCA),
although the proportion of adenocarcinomas in western Europe
and the United States is increasing to almost 50%, with no
difference in long-term outcomes between the two histological
types. Oesophageal cancer is a highly virulent disease with a 5-year
survival rate of 10–15% (Lenz et al, 1996; Bronckaers et al, 2009).
At presentation, approximately 50% of patients show distant
metastases and the remaining patients who initially present with
locoregional disease will eventually develop distant metastases.
There is no standard chemotherapeutic regimen for metastatic
oesophageal SCCA; hence, various kinds of chemotherapeutic
regimens have been investigated in an attempt to prolong survival
and improve the quality of life. 5-Fluorouracil (5-FU), cisplatin,
and epirubicin are widely used chemotherapeutic agents for gastric
and oesophageal cancers worldwide (Kim et al, 1993; Ross et al,
2002). One of the most commonly used regimens as first-line
chemotherapy in metastatic oesophageal cancer is the combination
of cisplatin and a 5-FU continuous infusion, with response rates
(RRs) ranging from 30 to 40% (Ilzuka et al, 1992; Bleiberg et al,
1997; Enzinger et al, 1999). However, the continuous infusion of
5-FU and cisplatin combination therapy requires indwelling
venous access, which may lead to venous thrombosis and sepsis,
hence making therapy burdensome to the patient with significant
toxicity.
Capecitabine (Xeloda, Hoffmann-La Roche Inc., Basel, CH, USA)
is an oral fluoropyrimidine prodrug that is transformed to FU in
several steps, the last of which is conversion of 50-deoxy-5-
fluorouridine to FU by thymidine phosphorylase (TP). In patients
with advanced oesophagogastric cancer, capecitabine combinations
Received 4 May 2010; revised 28 June 2010; accepted 6 July 2010;
published online 10 August 2010
*Correspondence: Dr Y-H Im; E-mail: imyh00@skku.edu
5These authors contributed equally in this study.
British Journal of Cancer (2010) 103, 845–851
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
shave generally shown good antitumour activity and highlight the
potential of capecitabine as a replacement for infusional 5-FU
(Cunningham et al, 2008; Kang et al, 2009). These results have
shown that capecitabine is not inferior to FU. In addition,
fluropyrimidine-related adverse events were similar in the
capecitabine and FU groups. Thus, considering troublesome
venous access, capecitabine may be a good substitute for 5-FU.
A phase II trial of our previous study tested the safety and
efficacy of capecitabine (1250mgm
–2twice daily for 2 weeks) with
cisplatin (60mgm
–2 on day 1 in 3-week cycles; capecitabine and
cisplatin (XP)) for chemonaive oesophageal SCCA and reported
promising results with RRs of 57.8% and a tolerable toxicity profile
(Lee et al, 2008), suggesting that a combination of capecitabine and
platinum is one of the most effective regimens for the treatment of
advanced oesophageal cancer. Capecitabine was designed to take
advantage of the increased levels of TP observed in tumours as
opposed to normal tissue, potentially allowing for selective toxicity
in tumours (Van Cutsem et al, 2001). Elevated levels of TP are
associated with tumour aggressiveness and poor prognosis
(Bronckaers et al, 2009). 5-FU is then either degraded by
dihydropyrimidine dehydrogenase (DPD) or anabolised to fluoro-
deoxyuridylate, which inhibits thymidylate synthase (TS). Thymi-
dylate synthase, the target enzyme of 5-FU, has been shown to be
an independent prognostic marker of 5-FU chemotherapy in
gastrointestinal tumours (Lenz et al, 1996, 1998; Shirota et al,
2001). Meropol et al (2006) evaluated TP, TS, and DPD for their
ability to predict a response to capecitabine when used in a first-
line metastatic setting, in an attempt to identify patients who may
have an altered response to a capecitabine/irinotecan regimen. The
role of TP and TS to identify predictive markers for the treatment
response to XP in oesophageal SCCA has not been defined.
Platinum compounds are additional key drugs in the treatment
of oesophageal SCCA. Resistance to platinum agents has been
attributed to enhanced tolerance to platinum DNA adducts,
decreased drug accumulation, and enhanced DNA repair. Impair-
ment of the DNA repair mechanism is important in the resistance
to cisplatin. The destruction of cells by cisplatin requires binding
of the drug to DNA and the creation of platinum-DNA adducts.
Some of these adducts establish covalent cross-linking between
DNA strands, thereby inhibiting DNA replication. Nucleotide
excision repair (NER) has a central role in DNA repair and
proteins of the NER pathway are thought to repair DNA damage
caused by platinum agents. The excision repair cross-complemen-
tation group 1 (ERCC1) enzyme has a rate-limiting role in the NER
pathway that recognises and removes cisplatin-induced DNA
adducts (Olaussen et al, 2006).
The significance of TS, TP, and ERCC1 expression in
oesophageal SCCA has not been studied in patients who have
been treated with capecitabine and platinum combination
chemotherapy. In this study, we determined the protein expression
of TS, TP, and ERCC1 by immunohistochemical (IHC) staining in
pretreatment biopsies of oesophageal tumour tissue specimens
from patients who received palliative first-line chemotherapy with
XP combination chemotherapy. This study was conducted to
evaluate the clinical implications of these proteins as biomarkers,
which could predict the outcome of XP chemotherapy.
PATIENTS AND METHODS
Patients
A total of 113 patients with recurrent or metastatic oesophageal
SCCA were treated with XP chemotherapy at the Samsung Medical
Center between July 2003 and December 2007, of whom 72 had
clinical data and paraffin tissue blocks available for immunohis-
tochemistry of TS, TP, and ERCC1 in this analysis. The median
duration of follow-up was 41 months, with a range of 18–70
months. Our study protocol was approved by the Institutional
Review Board of Samsung Medical Center.
Treatment
Patients received cisplatin (60mgm
–2 intravenously on day 1)
and capecitabine (1250mgm
–2per dose orally twice a day on days
1–14). Treatment cycles were repeated every 3 weeks until
documented disease progression, unacceptable toxicity, or patient
refusal. The treatment response was evaluated every two cycles by
RECIST, version 1.0.
IHC staining and scoring
Tumour specimens from patients who were diagnosed on the basis
of histological samples were evaluated for biomarker analyses. Full
specimen sections (4mm thick) were cut from paraffin blocks and
mounted on adhesive-coated or charged glass slides. An IHC
method was used to determine the level of protein expression for
TS, TP, and ERCC1.
Immunohistochemical staining was performed using the strep-
tavidin–biotin complex method and the TechMate 1000 auto-
mated staining system (DakoChemmate, Glostrup, Denmark). The
primary antibodies and working dilutions used were as follows: TS
mouse mAb (clone TS106/4H4B1, 1:50 dilution in Tris/EDTA
buffer (pH 9.0); Zymed, San Francisco, CA, USA) and TP mouse
mAb (PGF.44C, 1:100 dilution; NeoMarkers, Fremont, CA, USA).
Deparaffinised sections were treated with 3% hydrogen peroxide in
methanol for 10min to inhibit endogenous peroxidase. Sections
were immersed in 0.01 M citrate buffer (pH 6.0) and heated in a
pressure cooker for 30min. Sections were then incubated with
primary antibody for 50min at room temperature. Each section
was treated sequentially with a biotinylated secondary antibody
(antimouse immunoglobulin) and a streptavidin–peroxidase
complex (DakoChemmate). 3,30-Diaminobenzidine tetrahydro-
chloride was used as a chromogen, and Mayer’s haematoxylin
counterstain was applied. Experiments on negative controls
(isotype-matched irrelevant antibody) were run simultaneously.
For ERCC1 detection, mouse monoclonal antibody ERCC1
(8F1; NeoMarkers) was used at a dilution of 1:200 overnight in
a humidified chamber. The primary antibody was visualised with
an avidin–biotin complex (ABC) system (Dako, Carpinteria, CA,
USA). Slides were washed in TBS, the relevant biotinylated goat
antimouse IgG diluted at 1:100 was added, and the slides were
incubated for 20min at room temperature. The sections were
washed again in TBS and incubated for 10min in a solution of
streptavidin–ABC–horseradish peroxidase diluted at 1:100. Colour
was developed by adding 3,30-diaminobenzidine tetrahydro-
chloride (Immunotech, Cedex, France). Finally, the sections were
counterstained with Mayer’s haematoxylin.
For each patient, three full-specimen sections were analysed, one
slide each for TS, TP, and ERCC1. The slides were assessed without
the knowledge of clinical outcome by two experienced patholo-
gists. Thymidine synthase and TP protein expression levels were
detected in both the cytoplasm and nucleus, and ERCC1 showed
nuclear staining (Figure 1).
The intensity and extent of the IHC staining was graded on a
quantitative scale from 0 to 100% in proportion, except for ERCC1,
and on a semiquantitative scale from 0 to 3, as follows: 0¼no
staining; 1¼weak staining; 2¼strong staining; and 3¼very
strong staining. The area of most intense staining was graded on
a scale from 0 to 4, where 0¼no staining, 1¼0–10% staining of
tumour cells, 2¼10–25% staining of tumour cells, 3¼25–50%
staining of tumour cells, and 4¼450% staining of tumour cells. A
TS score was calculated by multiplying the intensity and extent of
grades. Thymidine synthase scores o6 were considered low, and a
score 46 was defined as high in this study. The same criteria were
applied for TP and ERCC1 staining results.
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The w
2 values of Fisher’s exact tests, as indicated, were applied for
the comparison of clinicopathological features of TS, TP, and
ERCC1 tumours. Progression-free survival (PFS) was calculated
from the first date of XP chemotherapy to the date of progression
or death in the case of patients who died without progression.
Overall survival (OS) was defined as the interval between the first
date of chemotherapy and death or up to the date of the last follow-
up evaluation. Both PFS and OS were calculated according to the
Kaplan–Meier method. All reported P-values are two-sided. The
contribution of prognostic variables to survival was analysed using
the log-rank test for univariate analysis and the Cox proportional
hazard model for multivariate analysis. The clinicopathological
variables and expressions of TS, TP, and ERCC1 were examined
for an association with the clinical outcome. The log-rank test was
used to measure the association between TS, TP, and ERCC1, and
survival. For quantitative analysis of TS and TP in terms of the
extent of positive staining, the ANOVA test was used with
response. We did not conduct survival analysis with quantitative
results. Statistical significance was regarded as significant when
Po0.05. All analyses were carried out using the Statistical Package
for the Social Science (version17.0; SPSS Inc., Chicago, IL, USA)
statistical software package.
RESULTS
Patient characteristics and clinical outcome
Between July 2003 and December 2007, 113 patients with advanced
oesophageal cancer received palliative chemotherapy at our
institution, with XP combination chemotherapy as a first-line
treatment. Among these 113 patients, tissue samples of 72 patients
were available for analysis of IHC staining of TS, TP, and ERCC1.
The patient baseline characteristics are listed in Table 1. All
patients had histologically proven SCCA of the oesophagus, and no
patient had adenocarcinomas of the gastro-oesophageal junction.
The median age was 62 years, with a range of 31–72 years. In all,
25 (34.7%) patients received adjuvant 5-FU and cisplatin (FP)
chemotherapy after surgical resection; 68 (94.4%) patients had an
Eastern Cooperative Oncology Group performance status of 0–1.
The sites of metastasis included the lymph nodes (76.4%), lung
(26.4%), liver (18.1%), pleura (11.1%), skin (6.9%), and bone
(5.6%).
Of the 72 subjects who were considered assessable for response
to therapy, 69 had an overall RR of 51.4%, with 2 complete
responses and 35 partial responses (51.4%). Ten (14.5%) patients
had stable disease, but 22 (30.6%) patients experienced clinical
or radiographic evidence of disease progression. Three (4.2%)
patients were not assessable because of loss to follow-up. The
patient population had a median of four cycles of the XP regimen.
The median time to PFS was 4.2 months (95% confidence interval
(CI) 3.0–5.4 months), and the median survival was 12.0 months
(95% CI 9.2–14.8 months). The median duration of follow-up was
41 months.
IHC staining results of TS, TP, and ERCC1 expression
Table 2 shows the IHC results of TS, TP, and ERCC1 expression
according to intensity and proportion. The number and percentage
of patients who had low scores are shown.
Relationship between treatment response and biological
marker expression
The association between TS, TP, and ERCC1, and response to XP,
as measured by IHC, is listed in Table 3. A high TS proportion,
high TS intensity, and high TS score predicted a response
(TSo25% vs TS X25%, RR 40.5 vs 59.5%, P¼0.009; TS intensity
0–1 vs 2–3, RR 45.9 vs 54.1, P¼0.030; TS score p6 vs TS
score46, RR 40.5 vs 59.5%, P¼0.005). High expression of TS and
TP was also significantly correlated with treatment response to the
XP regimen (high TS and TP vs low TS and TP, RR 54.1 vs 45.9%,
P¼0.022). High TS and TP expression with low ERCC1 expression
X400, TS X400, ERCC1 X400, TP 50 um 50 um 50 um
Figure 1 Immunohistochemical staining of TS, TP, and ERCC1 in oesophageal squamous cell cancer. (A) High staining intensity for TS. The TS staining
was predominantly a cytoplasmic granular pattern ( 400). (B) Positive sample with TP. The immunoreactivity was nuclear and cytoplasmic and it was highly
expressed in mononuclear cells ( 400). (C) High expression of ERCC1. The ERCC1 staining was strong and diffuse in the nucleus ( 400).
Table 1 Patients’ characteristics (n¼72)
Number of
patients (n¼72) %
Sex
Male 69 95.8
Female 3 4.2
Age, median (range) 62 (37–72)
Performance status
0–1 68 94.4
2 4 5.6
Previous adjuvant FP chemotherapy 25 34.7
XP cycle, median (range) 4 (1–12)
Metastatic sites
Lymph nodes 55 76.4
Lung 19 26.4
Liver 13 18.1
Pleura 8 11.1
Skin 5 6.9
Bone 4 5.6
Abbreviations: FP¼fluouracil and cisplatin; XP¼capecitabine and cisplatin.
TS, TP, and ERCC1 for oesophageal SCCA
S Lee et al
847
British Journal of Cancer (2010) 103(6), 845–851 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(0–2 vs 3) showed a significantly better response compared with
other levels of expression (high TS and TP and low ERCC1 vs other
levels of expression, RR 63.2 vs 36.8%, P¼0.016; Table 3, Figures
2–4). In addition, quantitative analysis, as well as TS and TP
extents, showed significant correlation with responses (RR 3.77,
Po0.0001 for TS extent (%); RR 4.12, P¼0.045 for TP extent by
ANOVA test, Table 3).
Univariate and multivariate analyses of factors associated
with prognosis
We investigated the prognostic significance of various clinico-
pathological factors in patients with metastatic oesophageal SCCA.
The univariate analysis showed that a high TS score, high TP score,
and low ERCC1 expression were important factors affecting the
prolongation of PFS and OS. Multivariate analysis was performed
on capecitabine biological markers separately and with the
platinum markers combined. Strong ERCC1 expression and a
low TS score were identified as independent risk factors for PFS
(hazard ratio (HR) 10.71, 95% CI 2.1–54.7, P¼0.004 for strong
ERCC1 expression; and HR 2.9; 95% CI 1.0–7.9, P¼0.044 for a
low TS score). Strong ERCC1 expression was the only unfavourable
independent determinant for OS (HR 3.73; 95% CI 1.39–10.0;
Table 4).
DISCUSSION
Thymidine synthase and TP have a key role in 5-FU resistance.
Thymidine synthase, an essential enzyme needed for DNA
synthesis, is the target enzyme of 5-FU. A number of studies have
Table 3 Association between TS, TP, and ERCC-1 and response (semiquantitative and quantitative analysis)
Response (CR+PR)
v
2 Relative risk, 95% CI
TS extent (3–4 vs 0–2) 59.5 vs 40.5% (P¼0.009) 3.70 (1.37–10.0)
TS intensity (2–3 vs 0–1) 54.1 vs 45.9% (P¼0.030) 3.03 (1.10–8.33)
TS score (extent   intensity) (4 6 vs 6 p) 59.5 vs 40.5% (P¼0.005) 6.67 (1.69–25.0)
High TS, TP expression (both high score vs others) 54.1 vs 45.9% (P¼0.022) 3.70 (1.23–11.11)
High TS, TP expression with low ERCC1 expression 63.2 vs 36.8% (P¼0.016) 3.45 (1.33–11.10)
Response (CR+PR)
ANOVA Relative risk
TS extent (%) Po0.0001 3.77
TP extent (%) P¼0.045 4.12
Abbreviations: ANOVA¼analysis of variance; CI¼confidence interval; CR¼complete response; ERCC1¼excision repair cross-complementation group 1; PR¼partial
response; TP¼thymidine phosphorylase; TS¼thymidine synthase. Intensity was graded on a semiquantitative scale from 0 to 3, where 0¼no staining, 1¼weak staining,
2¼strong staining, and 3¼very strong staining. The area of the most intense staining was graded on a scale from 0 to 4, where 0¼no staining, 1¼staining of 0–10% of tumour
cells, 2¼10–25% of tumour cells, 3¼staining of 25–50% of tumour cells, and 4¼staining of 450% of tumour cells. A TS score was calculated by multiplying the intensity and
extent grades. TS scores o6 were considered low, and score 46 were defined as high in this study. The same criteria were applied for TP and ERCC1 staining results.
Median PFS;
4.2 months
(95% CI; 3.0–5.4)
Median OS;
12.0 months
(95% CI; 9.2–14.8)
P
r
o
b
a
b
i
l
i
t
y
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
b
a
b
i
l
i
t
y
1.0
0.8
0.6
0.4
0.2
0.0
Months
0.0 6.0 12.0 18.0 24.0 30.0 36.0 42.0 48.0
Months
0.0 3.0 6.0 9.0 12.0 15.0 18.0 21.0
Figure 2 Kaplan–Meier curve for PFS and OS of XP in metastatic oesophageal SCCA.
Table 2 TS, TP, and ERCC1 by IHC staining
Number of patients
with low scores %
TS
Area (0–2 vs 3–4) 38/69 55.1
Intensity (0–1 vs 2–3) 40/69 58.0
TP
Area (0–2 vs 3) 23/72 31.9
Intensity (0–2 vs 3) 3/72 4.2
ERCC1
Area (0–2 vs 3) 22/41 53.7
Intensity (0–2 vs 3) 14/41 34.1
Abbreviations: ERCC1¼excision repair cross-complementation group 1;
IHC¼immunohistochemical; TP¼thymidine phosphorylase; TS¼thymidine
synthase. Score means multiplying the intensity and extent grades of the IHC.
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sinvestigated TS expression and survival in colorectal cancer, but
the data are conflicting (Popat et al, 2004). Some investigators have
reported a survival benefit for patients with a high TS expression
treated with 5-FU in adjuvant and metastatic colorectal cancer
(Johnston et al, 1995; Edler et al, 2002; Soong and Diasio, 2005). In
contrast to previous studies, different investigations have demon-
strated a significant benefit in patients with low intratumoural TS
levels (Allegra et al, 2002, 2003; Ciaparrone et al, 2006). Our results
are consistent with previous reports and can be explained by the
knowledge that high TS levels are most commonly associated with
a responsiveness to 5-FU in patients with advanced disease.
Although patients in this study were not randomly allocated to
the study, exploratory analysis showed that the HR associated
with capecitabine chemotherapy was 6.67 (95% CI 1.69–25.0) for
advanced oesophageal SCCA with a high TS score (46) compared
with a low TS score.
Thymidine phosphorylase is the marker of a more aggressive
and malignant tumour phenotype that has increased resistance to
cytotoxic agents because of the loss of apoptotic potential. This
study also examined the impact of TP expression and its
correlation with prognosis. Our study demonstrated a significant
association between TP expression and clinical outcome. Thymi-
dine phosphorylase expression was shown to be a positive
predictive factor for FU response. However, the prognostic role
of TP is not clear. Conflicting results have been reported in
different studies. Li et al (2004) evaluated the association between
TP-messenger RNA expression in tumour tissue and some
prognostic factors (grade, tumour size, lymph node status,
phase S cellular fraction, ploidy, and clinical variables) with no
statistically significant correlation. Yang et al (2002) analysed the
expression of TP in 182 breast cancer patients with evidence of an
association between TP expression, low grade, and low p53
expression. Thymidine phosphorylase-positive tumours seem to
have a longer time to progression and OS, with a limited effect on
angiogenesis. In contrast with these results, Tominaga et al (2002)
published a retrospective study on TP expression in 650 samples of
breast cancer. This study was not consistent with a previous report
of an increase in tumour response and prolongation of OS in
patients treated with FU and/or cisplatin-based chemotherapy for
gastrointestinal cancer.
Excision repair cross-complementation group 1, the structure-
specific DNA repair endonuclease responsible for 50 incision, has a
key role in the removal of adducts from genomic DNA through the
NER pathway. We found that low expression of ERCC1 correlated
significantly with a good response to systemic chemotherapy in
patients with metastatic oesophageal SCCA. Kim et al (2008)
reported that the low expression of ERCC1 correlated significantly
with a good response to preoperative chemoradiotherapy
in patients with oesophageal cancer, suggesting that ERCC1
expression may determine that the benefit of preoperative
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Figure 3 Thymidine synthase and TP expression and PFS.
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Figure 4 Excision repair cross-complementation group 1 expression
and OS.
Table 4 Multivariate Cox-regression hazard model for PFS and OS
PFS OS
P-value HR 95% CI P-value HR 95% CI
Low TS score 0.044 2.87 1.03 7.99 0.356 1.22 0.38 3.46
Strong ERCC1 0.004 10.71 2.10 54.71 0.009 3.73 1.39 10.04
Hepatic metastasis 0.118 2.57 0.79 8.41 0.235 1.11 0.03 2.13
Abbreviations: CI¼confidence interval; ERCC1¼excision repair cross-complemen-
tation group 1; HR¼hazard ratio; OS¼overall survival; PFS¼progression-free
survival; TS¼thymidine synthase.
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schemoradiotherapy may be more effective than immediate surgery
in patients with a low ERCC1 expression. In contrast, immediate
oesophagectomy may be as effective as preoperative chemora-
diotherapy in patients with a high ERCC1 expression. These results
were consistent with a prospective study in non-small-cell
lung cancer, which showed that adjuvant platinum-based
chemotherapy, compared with observation, significantly pro-
longed survival among patients with ERCC1-negative tumours
(Olaussen et al, 2006). Jun et al (2008) compared their study of
head and neck cancer treated with cisplatin-based concurrent
chemoradiation with a study of non-small-cell lung cancer and
showed that the proportion and pattern of ERCC1 expression
varied according to tumour type. Multivariate analysis revealed
that low expression of ERCC1 was an independent factor
associated with a lower risk of cancer death. This result was also
consistent with a previous report of an increase in tumour
response and prolongation of OS in patients with oesophageal
SCCA treated by cisplatin-based chemotherapy (Warnecke-Eberz
et al, 2004; Joshi et al, 2005). Out data support the hypothesis that
enhanced DNA repair decreases the benefit of platinum-based
treatment.
If the combination of these three markers reflects the response
and toxicity of the XP regimen in patients with metastatic
oesophageal SCCA, we can predict who benefits from this regimen.
As only a relatively small proportion of patients seem to benefit
from systemic chemotherapy in metastatic oesophageal SCCA,
considerable effort has been directed towards finding biomarkers
that can accurately predict tumour response. Currently, however,
there is insufficient evidence to justify the incorporation of these
or any other candidate predictive markers into routine clinical
practice for the selection of oesophageal cancer patients to receive
XP. If one could identify the patients likely to respond to a
particular regimen, therapy could subsequently be tailored
accordingly and the survival rate could be improved.
The limitation of this study included the inherent weakness of
IHC staining, such as its semiquantitative nature, different
antibodies used in various studies, inter or intraobserver variation,
the variable cutoffs for TS, TP, and ERCC1 positivity, and the
effects of tissue ageing. In addition, the number of patients was
relatively small, and the study was retrospective in design. These
correlative studies must be viewed as hypothesis generating and
interpreted with caution because of the small sample sizes and
limitation of a retrospective study.
In conclusion, this study has demonstrated that TS, TP, and
ERCC1 expressions show promising markers for response and
survival prediction of XP chemotherapy in patients with recurrent
or metastatic oesophageal SCCA. Further prospective randomised
studies are needed to confirm our results.
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